Therapies on the horizon for cholesterol reduction

Statins are powerful agents for the reduction of low‐density lipoprotein cholesterol (LDL‐C) and reduction of cardiovascular risk. Newly developed statins with increased potency, such as rosuvastatin (CrestorTM) and NK‐104 (in earlier clinical development), are capable of achieving marked LDL‐C redu...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cardiology (Mahwah, N.J.) N.J.), 2001-08, Vol.24 (S3), p.24-27
Main Author: Brown, W. Virgil
Format: Article
Language:English
Subjects:
Acetates - therapeutic use
Anticholesteremic Agents - therapeutic use
avasimibe
Azetidines - therapeutic use
bile transport inhibitors
Carrier Proteins - antagonists & inhibitors
Cholestyramine Resin - therapeutic use
Ezetimibe
Fluorobenzenes - therapeutic use
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Hydroxysteroid Dehydrogenases
Hypercholesterolemia - drug therapy
Membrane Glycoproteins
NK‐104
Pyrimidines
rosuvastatin
Rosuvastatin Calcium
Sterol O-Acyltransferase - antagonists & inhibitors
Sulfonamides
Sulfonic Acids - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Statins are powerful agents for the reduction of low‐density lipoprotein cholesterol (LDL‐C) and reduction of cardiovascular risk. Newly developed statins with increased potency, such as rosuvastatin (CrestorTM) and NK‐104 (in earlier clinical development), are capable of achieving marked LDL‐C reductions. Cholesterol‐lowering agents with mechanisms of action distinct from those of the statins are in active development. These include bile transport inhibitors. such as improved bile acid‐absorbing resins and specific inhibitors of the ileal Na+/bile acid cotransporter. There are also specific inhibitors of cholesterol absorption, such as ezetimibe, which may provide cholesterol lowering that is additive to that achieved with statin treatment. Another approach is to reduce cardiovascular risk by modifying atherosclerotic processes within the arterial wall, as represented by the acyl CoA:cholesterol acyltransferase (ACAT) inhibitor avasimibe; ACAT inhibitors may reduce atherosclerotic lesions by inhibiting macrophage cholesterol storage.
ISSN:0160-9289
1932-8737
DOI:10.1002/clc.4960241506